Find clinical trials for Melanoma in Birmingham, AL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer

Carcinoma

Squamous Cell Carcinoma of Head and Neck

Non-Small-Cell Lung Carcinoma

Renal Cell Carcinoma

Lung Cancer

Squamous Cell Carcinoma

Melanoma trials near Birmingham, AL, USA:

Locations recently updated

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling

Melanoma

Unresectable Melanoma

Biological: Pembrolizumab with Optional Crossover Period

Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Birmingham, Alabama, United States and 32 other locations

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling

Ocular Melanoma

Choroidal Melanoma

Device: Suprachoroidal Microinjector

Drug: Sham Treatment

Phase 3

Aura Biosciences

Birmingham, Alabama, United States and 37 other locations

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...

Enrolling

Melanoma (Skin)

Metastatic Melanoma

Drug: Ipilimumab

Drug: ANV419

Phase 1, Phase 2

Anaveon

Birmingham, Alabama, United States and 24 other locations

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting

Melanoma

Biological: Nivolumab

Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)

Birmingham, Alabama, United States and 171 other locations

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)

and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease (NED) who are at high risk for recur...

Active, not recruiting

Melanoma

Biological: Nivolumab

Other: Placebo

Phase 3

Bristol-Myers Squibb (BMS)

Birmingham, Alabama, United States and 128 other locations

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

in patients with locally advanced unresectable or metastatic melanoma with BRAF V600 mutation. A total of approximately 900 patients will be...

Active, not recruiting

Melanoma

Drug: MEK162

Drug: vemurafenib

Phase 3

Pfizer

Birmingham, Alabama, United States and 378 other locations

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

+ cobimetinib + vemurafenib in patients with previously untreated BRAFv600 mutation-positive metastatic or unresectable locally advanced melanoma...

Active, not recruiting

Melanoma

Drug: Atezolizumab Placebo

Drug: Vemurafenib

Phase 3

Roche

Birmingham, Alabama, United States and 115 other locations

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects...

Enrolling

Non-melanoma Skin Cancer

Melanoma (Skin)

Biological: RP1

Biological: nivolumab

Phase 2

Replimune

Birmingham, Alabama, United States and 52 other locations

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst)

This Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in...

Active, not recruiting

Advanced Melanoma

Advanced Head and Neck Squamous Cell Carcinoma

Drug: Pembrolizumab 25 MG/ML [KEYTRUDA®]

Drug: CyPep-1

Phase 1, Phase 2

Cytovation

Birmingham, Alabama, United States and 24 other locations

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected...

Enrolling

Advanced Unresectable Solid Tumor

Metastatic Solid Tumor

Drug: Toripalimab

Drug: TAB004

Phase 1

TopAlliance Biosciences

Birmingham, Alabama, United States and 23 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Melanoma in .css-epvm6{white-space:nowrap;}Birmingham, AL

Related conditions:

Melanoma trials near Birmingham, AL, USA:

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma (CoMpass)

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (CheckMate76K)

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma (COLUMBUS)

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (Catalyst)

Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

Find clinical trials for Melanoma in Birmingham, AL